Prevalence of Primary Aldosteronism Among Hypertensive Patients With Atrial Arythmia (HAPAA)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04115280|
Recruitment Status : Recruiting
First Posted : October 4, 2019
Last Update Posted : April 22, 2020
Atrial arrhythmia is the most frequent cardiac arrhythmia. It is a source of significant morbidity.
Hypertension is a major risk factor for atrial arrhythmias. Primary hyperaldosteronism (PA) is a common cause of secondary hypertension, associated with a high prevalence of arrhythmias with a specific, sometimes curative, treatment. The purpose of the study is to show that the prevalence of PA among hypertensive patients under 65 years old with atrial arrhythmia is high, justifying systematic screening.
|Condition or disease||Intervention/treatment||Phase|
|Primary Aldosteronism Atrial Fibrillation||Diagnostic Test: Primary Hyperaldosteronism diagnostic||Not Applicable|
Atrial arrhythmia is the most frequent cardiac arrhythmia, affecting one million patients in France. It is a source of significant morbidity, a major deterioration in the quality of life and considerable health expenditure.
Hypertension is a major and modifiable risk factor for atrial arrhythmias. Primary hyperaldosteronism is a common cause of secondary hypertension, associated with a high prevalence of arrhythmias, but also stroke, coronary artery disease, heart and kidney failure. This form has a specific treatment, sometimes curative.
The objective of this study is to show that the prevalence of primary hyperaldosteronism among patients under 65 with atrial arrhythmias is high, justifying systematic screening in this population.
The investigators will consecutively include 65-year-old hypertensive patients hospitalized in the department with atrialarrhythmia. They will benefit from an aldosterone to renin ratio assay under standardized conditions at 3 months.
Patients whose aldosterone (pmol/l) to renin (mUI/l) ratio is greater than 64 will benefit from saline infusion test if necessary and adrenal scan. Patients with a definite diagnosis who would prefer surgical treatment will benefit from adrenal venous catheterization.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||300 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Prevalence of Primary Aldosteronism Among Hypertensive Patients Younger Than 65 Years Old With Atrial Arythmia|
|Actual Study Start Date :||April 16, 2020|
|Estimated Primary Completion Date :||October 16, 2022|
|Estimated Study Completion Date :||October 16, 2022|
- Diagnostic Test: Primary Hyperaldosteronism diagnostic
blood sample to obtain the aldosterone to renin ratio
- Evaluation of the prevalence of primary hyperaldosteronism [ Time Frame: Data collected after the saline infusion test (6-month visit) ]Prevalence of primary hyperaldosteronism among the enrolled population.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04115280
|CHU de Bordeaux||Not yet recruiting|
|Contact: Josselin DUCHATEAU 05 57 65 69 69 firstname.lastname@example.org|
|CH de Pau||Recruiting|
|Contact: Romain BOULESTREAU 05 59 92 48 83 email@example.com|
|Contact: Alice SERIS 0559726997 firstname.lastname@example.org|